| Dr Christiana Meng Zhang, MD | |
|
10753 Falls Rd Ste 325, Lutherville, MD 21093 | |
| (410) 583-2774 | |
| (410) 583-2883 |
| Full Name | Dr Christiana Meng Zhang |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 10753 Falls Rd Ste 325, Lutherville, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124430863 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | D83570 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Johns Hopkins Home Health Services, Inc | Baltimore, MD | Home health agency |
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Johns Hopkins Bayview Medical Center | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 4981745098 | 571 |
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.
If a drug was developed to block a key protein linked to the onset of Huntington's Disease, it could have a clear path to the part of the brain most affected by the disease, while not bothering other parts of the brain and body, said distinguished neuroscientist Solomon H. Snyder, MD, to an audience of about 300 students and faculty at the University of Maryland, Baltimore (UMB).
Data from the PRospective Observational cohort Study on patients with Inflammatory bowel disease receiving Therapy with BIOsimilars (PROSIT-BIO) in patients with ulcerative colitis (UC) and Crohn's disease (CD) has been presented at the Italian Group for the Study of IBD (IG-IBD), VII National Congress, Palermo, Italy.
A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.
› Verified 8 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.
If a drug was developed to block a key protein linked to the onset of Huntington's Disease, it could have a clear path to the part of the brain most affected by the disease, while not bothering other parts of the brain and body, said distinguished neuroscientist Solomon H. Snyder, MD, to an audience of about 300 students and faculty at the University of Maryland, Baltimore (UMB).
Data from the PRospective Observational cohort Study on patients with Inflammatory bowel disease receiving Therapy with BIOsimilars (PROSIT-BIO) in patients with ulcerative colitis (UC) and Crohn's disease (CD) has been presented at the Italian Group for the Study of IBD (IG-IBD), VII National Congress, Palermo, Italy.
A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.
› Verified 8 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1902332133 PECOS PAC ID: 4981745098 Enrollment ID: O20170818000085 |
News Archive
Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.
If a drug was developed to block a key protein linked to the onset of Huntington's Disease, it could have a clear path to the part of the brain most affected by the disease, while not bothering other parts of the brain and body, said distinguished neuroscientist Solomon H. Snyder, MD, to an audience of about 300 students and faculty at the University of Maryland, Baltimore (UMB).
Data from the PRospective Observational cohort Study on patients with Inflammatory bowel disease receiving Therapy with BIOsimilars (PROSIT-BIO) in patients with ulcerative colitis (UC) and Crohn's disease (CD) has been presented at the Italian Group for the Study of IBD (IG-IBD), VII National Congress, Palermo, Italy.
A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christiana Meng Zhang, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-2704 | Dr Christiana Meng Zhang, MD 10753 Falls Rd Ste 325, Lutherville, MD 21093 Ph: (410) 583-2774 |
News Archive
Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.
If a drug was developed to block a key protein linked to the onset of Huntington's Disease, it could have a clear path to the part of the brain most affected by the disease, while not bothering other parts of the brain and body, said distinguished neuroscientist Solomon H. Snyder, MD, to an audience of about 300 students and faculty at the University of Maryland, Baltimore (UMB).
Data from the PRospective Observational cohort Study on patients with Inflammatory bowel disease receiving Therapy with BIOsimilars (PROSIT-BIO) in patients with ulcerative colitis (UC) and Crohn's disease (CD) has been presented at the Italian Group for the Study of IBD (IG-IBD), VII National Congress, Palermo, Italy.
A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.
› Verified 8 days ago
Dr. Rameen James Molavi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10755 Falls Rd, Suite 200, Lutherville, MD 21093 Phone: 410-583-7112 Fax: 410-583-7113 | |
John H Fetting, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10753 Falls Rd, Lutherville, MD 21093 Phone: 410-583-2970 | |
John P Affronti, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10803 Falls Road, Pavillion Iii, Lutherville, MD 21093 Phone: 410-616-7650 Fax: 410-616-7651 | |
Donald Schlott, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 10755 Falls Rd, Lutherville, MD 21093 Phone: 410-583-2727 | |
Dr. Robert Benjamin Stoltz, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1447 York Rd, Suite 605, Lutherville, MD 21093 Phone: 410-821-1300 Fax: 410-821-0201 | |
Dr. Karen Tapawan Chen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1447 York Rd, Lutherville, MD 21093 Phone: 410-339-5500 | |
Dr. Asima Rahman, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1447 York Rd, Suite 100, Lutherville, MD 21093 Phone: 410-339-5500 Fax: 410-339-5695 |